There are five subtypes of muscarinic receptor (M1–M5) that are expressed in different tissues and have diverse roles in processes such as cognition, salivation, sight, and bowel function.

As per the Brain and Behavior Research Foundation, it combines two compounds called xanomeline and trospium chloride. This is ...

A Vanderbilt University patent discloses new muscarinic M4 receptor positive allosteric modulators and agonists reported to be useful for the treatment of Alzheimer’s disease, pain, schizophrenia, ...

The drug – a selective muscarinic M4 receptor positive allosteric modulator (PAM) – is designed to have limited effect on dopamine neurotransmission, a mechanism thought to contribute to ...

Xanomeline was first developed in the 1990s and trialed in patients with Alzheimer’s disease, appearing to improve cognitive function ... Trospium is a muscarinic receptor-blocking drug that ...

Protein-protein interactions govern a large number of biological processes. A number of cell surface and nuclear receptors mediate their actions via dimerization. While this has been well ...

Cobenfy, targeting M1 and M4 muscarinic receptors, represents a significant advancement ... CANTAB digital assessments provide accurate and objective measures of cognitive function in clinical trials.

Nxera and Neurocrine entered a collaboration and licensing agreement in 2021 to develop a portfolio of novel clinical and preclinical subtype-selective muscarinic M4, M1 and dual M1/M4 receptor ...